Science Corp Prepares First Human Brain Sensor Trial With Yale Neurosurgeon
Science Corporation, founded by ex-Neuralink president Max Hodak, is preparing to place its first 520-electrode recording sensor in a human brain. Yale neurosurgery chair Dr. Murat Günel has been appointed medical director, with an opportunistic trial design that piggybacks on existing cranial surgeries to minimize additional risk.
In a significant milestone for neurotechnology, Science Corporation has announced it is preparing to place its first sensor in a human brain, enlisting Yale School of Medicine’s chief neurosurgeon to lead the effort. The development marks a new chapter for the startup, which is pursuing a fundamentally different approach to brain-computer interfaces than any other company in the space.
Science Corp was founded by Max Hodak, who served as president of Neuralink until his departure in 2021. Having watched from the sidelines as Neuralink completed its first human implant in January 2024, Hodak is now advancing his own vision for what comes next in BCI technology — one that bets not on better electronics, but on merging electronics with living biology.
The Biohybrid Difference
Every current BCI implant faces a fundamental long-term problem: the brain treats foreign objects as threats. Rigid silicon electrode arrays — whether Neuralink’s, Synchron’s, or anyone else’s — trigger an immune response that gradually encases the device in scar tissue. Over months or years, this glial scarring degrades signal quality and can render the implant ineffective. The device that restored cursor control or communication on day one may provide only noise by year three.
Science Corp’s proposed solution is radical: embed living neurons in the implant itself. In the final version of the device, lab-grown neurons would be incorporated into the interface layer. Light pulses would stimulate these embedded cells, which would then communicate with surrounding brain tissue using the brain’s own biological signaling — synaptic connections rather than electrical fields bridging the gap between silicon and cell.
The hypothesis is that a biohybrid interface, rather than fighting the brain’s immune system, would integrate with it. The lab-grown neurons, themselves biological, could form stable synaptic connections with the patient’s native neural circuitry in ways that a rigid electrode never can.
The Cautious First Step
The first human implant will not include the biohybrid components. Science Corp is starting with a 520-electrode recording-only sensor — a conservative device designed to prove safety before complexity. The goal is to demonstrate that the sensor array can sit safely on the cortical surface and capture meaningful, interpretable neural signals without causing harm.
This is standard practice in medical device development: establish a safety baseline before adding the experimental elements. The biohybrid layer — the living neurons that represent the company’s core technological differentiation — will come in later device generations, once the foundational recording hardware is validated in humans.
A Pragmatic Trial Design
Rather than spending years recruiting patients specifically for a BCI study — a costly, slow process that requires patients willing to undergo brain surgery for a speculative device — Science Corp and Dr. Günel have devised a more efficient path to the first human placement.
The plan is to identify patients who already require significant cranial surgery for independent medical reasons: tumor removal, aneurysm repair, or other neurosurgical procedures. With the skull already open and the brain exposed, placing a small surface sensor adds minimal additional time and risk. The patient benefits from no additional surgical risk; Science Corp gains its first real-world safety data.
Dr. Murat Günel — chair of the Department of Neurosurgery at Yale School of Medicine, neurosurgeon-in-chief of Yale New Haven Health, and one of the most prominent neurovascular surgeons in the United States — was appointed Science Corp’s medical director for brain-computer interfaces at the end of March 2026, following two years of discussions with Hodak. His institutional standing lends the program significant scientific and regulatory credibility.
Günel himself is measured in his expectations for timing. He described a 2027 start date for the first trial as “optimistic” — a word that in clinical trial parlance signals meaningful uncertainty rather than confident projection.
PRIMA: The Near-Term Commercial Product
While the cortical BCI program represents Science Corp’s long-term vision, the company already has a commercial product considerably closer to market: PRIMA, a sub-grain-of-rice retinal implant that pairs with camera-equipped glasses to restore functional vision in patients with advanced macular degeneration.
PRIMA operates on a similar biohybrid principle to the cortical BCI — light from the camera glasses stimulates the implanted chip, which in turn stimulates remaining retinal neurons — though in a more accessible anatomical location than the brain. The company has filed for CE mark approval in the European Union and anticipates clearance by mid-2026, which would allow it to launch commercially on the continent.
The retinal product serves a dual strategic purpose: it generates near-term revenue, and it provides real-world clinical data on the safety and longevity of the company’s underlying biohybrid technology in a human implant setting.
Funding and Competitive Position
Science Corp raised $230 million in a Series C round in March 2026, led by Lightspeed Venture Partners and Khosla Ventures, with participation from Y Combinator, IQT, and Quiet Capital. The round brought total funding to $490 million at a $1.5 billion valuation.
The BCI competitive landscape has filled rapidly since Neuralink’s first human implant. Synchron has implanted multiple patients with its endovascular Stentrode, which accesses the motor cortex through blood vessels rather than open surgery. Precision Neuroscience, also founded by Neuralink alumni, is developing a thin-film ECoG array similar to what Science Corp plans for its first human recording — aiming to maximize electrode coverage while minimizing brain penetration.
Paradromics and BrainGate represent the academic and DARPA-funded end of the spectrum, focused on high-channel-count recording for research applications. And Neuralink itself has now accumulated multiple years of human data, with reported capabilities including wireless cursor control via thought alone.
The Long Game
What sets Science Corp apart is its insistence that the future of BCI is not more electrodes or better wireless bandwidth, but a genuine integration of biology and electronics at the interface. Whether lab-grown neurons can survive in vivo, form stable and functional synaptic connections with native circuitry, and reliably transduce signals over years rather than months is a question that no one has yet answered in humans.
The stakes are high. If the biohybrid approach works, Science Corp may have solved the chronic implant failure problem that has limited every BCI system ever built. If it doesn’t — if the embedded neurons fail to integrate, or integrate unpredictably — the company will need to fall back on conventional electrode technology in which it faces well-funded, more experienced competitors.
For now, the company is moving methodically: prove the recording hardware first, build clinical credibility through the retinal product, and pursue the biohybrid ambition in parallel. It is, as Hodak has described it, playing a very long game — one measured in decades rather than product cycles.